scispace - formally typeset
Search or ask a question

Is adenocarcinoma of the breast a cancerous condition? 

Answers from top 12 papers

More filters
Papers (12)Insight
If such a condition really exists, it may be possible by its elimination to prevent the occurrence of cancer; however, many of these so-called precancerous lesions never become cancerous, and if cancer develops in such a breast it does not mean that cancer originated in the precancerous lesion.
Relationships between breast cancer and each medical condition examined are biologically plausible, and relevant in terms of public health.
However, sulfomucins were demonstrated in 30.5% of cases; this fact points to add breast carcinoma to the group of neoplasms that may present as a metastatic sulfomucin‐producing adenocarcinoma.
In conclusion, the current study demonstrates that tumor nuclear DNA content is a strong indicator of prognosis in patients suffering from invasive breast adenocarcinoma.
Given the rarity of this condition, guidelines for therapy are unavailable; we therefore suggest looking to the current management of breast cancer in order to establish a sensible approach.
Vulva lactating adenoma is rare and may be misdiagnosed as adenocarcinoma in frozen section and aspiration cytology if breast tissue is not anticipated.
After the operation the pathological examination revealed a primary squamous cell carcinoma of the breast. The presentation of squamous cell carcinoma could be similar to that of an adenocarcinoma.
Our patient, with a hormonally responsive adenocarcinoma of the breast and without systemic metastases, illustrates that meningeal carcinomatosis, like other forms of breast cancer metastasis, can run an indolent course.
Carcinoma of the breast is the condition which most
Review of the cytology literature shows that this condition frequently mimics the cytologic features of a number of benign and malignant breast lesions, thus representing not only an important potential pitfall in the diagnosis of carcinoma but also a differential diagnosis to consider in a variety of breast lesions.
Pure myoepithelial carcinoma of the breast adopts an aggressive clinical course with an outcome comparable to poorly differentiated adenocarcinoma of the breast.
Their histological appearance may mimic ductal adenocarcinoma of the breast.

See what other people are reading

What is the difference between small cell lung cancer and non-small cell lung cancer?
4 answers
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer with distinct characteristics. SCLC is a high-grade neuroendocrine tumor, representing about 15% of lung cancers, known for early relapse and low survival rates. On the other hand, NSCLC encompasses various histological entities like adenocarcinoma, squamous carcinoma, and large cell carcinoma, being the most common form of lung cancer globally. NSCLC patients often present in advanced stages, leading to limited life expectancy and a poor short-term prognosis. While SCLC has limited treatment advancements over the years, recent studies have identified four biologically distinct subtypes within SCLC, each responding differently to new treatments, offering hope for improved survival rates.
How effective is using Xception for breast cancer detection compared to other deep learning models?
5 answers
The effectiveness of using Xception for breast cancer detection compared to other deep learning models is significant. Studies have shown that deep learning techniques, including Xception, have achieved high accuracy rates in diagnosing breast cancer from X-ray mammograms. Specifically, the proposed AMAN model utilizing Xception has demonstrated promising results in classifying breast cancer with an accuracy of 95.15%. Additionally, research has highlighted the superiority of deep learning techniques, such as Xception, in detecting breast cancer from histopathological images, showcasing their potential in improving diagnostic accuracy. Xception, along with other deep learning models, has been instrumental in enhancing the detection and classification of breast cancer, offering a cost-effective and efficient approach to diagnosis.
What are the changes of estrogen levels during menstrual cycles of PMS patients?
5 answers
Estrogen levels fluctuate during the menstrual cycle in patients with premenstrual syndrome (PMS). Research indicates that estrogen concentrations peak twice during the menstrual cycle. Studies have shown that estrogen levels in blood plasma do not significantly correlate with depression or anxiety ratings in Taiwanese women with PMS. Additionally, cycling hamsters injected with PMS displayed increased peripheral estrogen levels. Furthermore, estrogen concentrations in breast subcutaneous adipose tissue fluctuate during the menstrual cycle, with lower levels observed in the follicular phase in women with estrogen receptor-positive breast cancer. These findings suggest that estrogen levels vary throughout the menstrual cycle in PMS patients, potentially impacting symptoms and physiological processes.
What are the potential advantages of using nanoparticle-based drug delivery systems in treatment of cancer?
5 answers
Nanoparticle-based drug delivery systems offer several advantages in cancer treatment. They provide reduced toxicity, improved permeability, and accurate targeting of tumor cells, overcoming limitations of conventional treatments. These systems enable targeted drug delivery, increasing drug concentration at the tumor site while reducing side effects on normal tissues. Lipid-based nanoparticles, in particular, show promise due to their biocompatibility, biodegradability, and loading capacity, enhancing treatment efficacy with minimal systemic effects. Nanoparticles can optimize drug circulation time and target drug efficacy through passive and active targeting strategies, interacting with specific receptors overexpressed in cancer cells. Additionally, nanoparticle systems can be tailored for synergistic delivery of nucleic acids and chemotherapeutic drugs, enhancing therapeutic outcomes and overcoming multidrug resistance in cancer cells.
What role does IL-6 play in hepatic and pancreatic stellate cells?
5 answers
IL-6 plays a crucial role in both hepatic and pancreatic stellate cells. In hepatic stellate cells (HSCs), IL-6 is secreted as part of the senescence-associated secretory phenotype, promoting liver regeneration by activating signaling pathways like STAT3, YAP, and ERK1/2. In pancreatic stellate cells (PSCs), IL-6 production contributes to pancreatic cancer progression by inducing the accumulation of myeloid-derived suppressor cells through the STAT3 pathway. Additionally, in hepatocytes, IL-6 protects against ischemia-reperfusion injury by activating the STAT3 signaling pathway and promoting autophagy, ultimately alleviating apoptosis and improving cell viability. Therefore, IL-6 plays diverse roles in both hepatic and pancreatic stellate cells, influencing processes like regeneration, cancer progression, and cell protection.
What role does IL-6 play in T cell migration in cancer?
4 answers
IL-6 plays a crucial role in T cell migration in cancer by influencing various aspects of the immune response. IL-6 is known to modulate T cell functions, including differentiation and activation, which can impact the immune response against tumors. Additionally, IL-6 signaling affects the migration of lymphocytes in high endothelial venules (HEV) and influences the activation and distribution of immune responses. Furthermore, impaired IL-6 signaling in peripheral blood T cells in breast cancer patients is associated with blunted Th17 differentiation, highlighting the importance of intact IL-6 signaling in controlling cancer progression and potentially serving as a predictive biomarker for clinical outcomes. Overall, IL-6's involvement in T cell migration underscores its significance in shaping the immune landscape within the tumor microenvironment.
What are the her-2 positive brest cancer cell lines used for xenograft model?
5 answers
The HER2-positive breast cancer cell lines used for xenograft models include MDA-MB-453, UACC-893, and HCC-202. Additionally, a novel HER2-positive breast cancer cell line, CK-MB-1, was established from a trastuzumab-resistant patient and utilized for xenograft tumor models in zebrafish and immunodeficient mice. Furthermore, three basal/HER2+ breast cancer cell lines, ZJU-0327, ZJU-0725, and ZJU-1127, were established from Chinese patients and evaluated in athymic nude mouse xenograft models, demonstrating high invasiveness and tumorigenicity. These cell lines provide valuable models for studying HER2-positive breast cancer metastasis and drug resistance in preclinical research settings.
Can regular consumption of certain herbs reduce the risk of developing melanoma?
5 answers
Regular consumption of specific herbs can indeed help reduce the risk of developing melanoma. Ayurveda herbs like Azadirachta indica, Ocimum tenuiflorum, Phyllanthus emblica, Santalum album, Tinospora cordifolia, and Withania somnifera have shown anti-oncogenic and chemopreventive properties, making them beneficial in preventing melanoma skin cancer. Additionally, natural products from medicinal plants have demonstrated potential as anticancer agents against melanoma, inhibiting cell viability and metastasis. Furthermore, phytoconstituents like carotenoids, flavonoids, polyphenols, piperine alkaloid, and sulforaphane have been identified as having high anticancer potential, particularly in the treatment of melanoma, emphasizing the importance of herbal phytoconstituents in melanoma chemoprevention and treatment.
Protein histidine kinases involved in breast cancer?
5 answers
Protein kinases play a crucial role in breast cancer development and progression. Various studies have highlighted the significance of different protein kinases in breast cancer. For instance, the emergence of targeted therapies, such as small-molecule kinase inhibitors, has revolutionized cancer treatment, including breast cancer. Additionally, the PKD family, particularly PKD2 and PKD3, have been found to be overexpressed in breast cancer, influencing cell proliferation and metastasis. Moreover, the DNA salvage pathway protein thymidine kinase 1 (TK1) has been implicated in breast cancer aggressiveness and cell cycle control, suggesting its potential as a biomarker and therapeutic target. Overall, protein kinases like PKD2, PKD3, and TK1 are crucial players in breast cancer pathogenesis, offering promising avenues for targeted therapies and diagnostic strategies.
Is there a relation between hydroxymethylation and kisspeptin-1 in cancer?
5 answers
Hypermethylation of the Kisspeptin-1 (Kiss1) gene has been implicated in various cancers, affecting its expression and potentially contributing to cancer progression. Kiss1 is known for its role in metastasis suppression, and its loss in tumor cells is associated with a more aggressive phenotype. Studies have shown that aberrant methylation patterns of genes like Kiss1 can serve as diagnostic biomarkers in colorectal cancer (CRC) and other malignancies. Additionally, the epigenetic silencing of Kiss1 through hypermethylation has been observed in bladder cancer, leading to low gene expression and poor clinical outcomes. Therefore, there is a clear relationship between hypermethylation and the regulation of Kisspeptin-1 in cancer, highlighting its potential as a target for therapeutic interventions and prognostic assessments.
What is the genetic basis of collision tumors compared to single histological tumors?
4 answers
Collision tumors, characterized by the coexistence of two distinct tumor types in the same organ, exhibit unique genetic profiles compared to single histological tumors. Studies have shown that collision tumors can harbor different molecular alterations in each component. For instance, a case of primary lung adenocarcinoma with mucosa-associated lymphoid tissue (MALT) lymphoma displayed specific molecular characteristics in each tumor type. In contrast, single histological tumors typically exhibit a more uniform genetic makeup within the tumor. Collision tumors, such as the reported case of primary intracranial collision tumors, may present with a combination of genetic alterations from each tumor component, highlighting the complexity of their genetic basis. This distinct genetic heterogeneity in collision tumors underscores the importance of accurate molecular analyses for diagnosis and treatment planning.